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Abstract
Mycophenolic acid (MPA) has been previously reported as an inhibitor of the chikugunya virus (CHIKV)
with an EC50 value of 0.2 µM. We used MPA as a lead compound designing and synthesizing a series of
isatins and benzolactones in a typical medicinal chemistry program. The synthesis and testing of 19
derivatives produced compounds with no desired activity which prompted us to retest the lead compound,
MPA. We can reveal that MPA shows no anti-CHIKV activity and therefore needs to be reassessed as a
lead compound for this target.

Introduction
Chikungunya virus (CHIKV) is a pathogen belonging to the genus Alphavirus, family Togaviridae. It is
mainly transmitted through the bite of an infected Aedes aegypti or A. albopictus mosquito, and the
infection is characterized by a typical and devastating arthritis disease. The first report on a patient with
chikungunya fever dates from 1952.1 After five decades of only sporadic cases, a series of large epidemics
occurred, starting in la Réunion island (2005-2006) during which almost 1:3 of the population became
infected, progressing around the Pacific Ocean through India (1.4 to 6.5 million cases in 2006-2007), in
2009 followed by 3,000 and 42,000 cases in Malaysia and Thailand, respectively.2,3 In Europe, as well as
multiple imported cases, the first patients with indigenous CHIKV transmission were documented in Italy
in 2007.4,5 Presently, CHIKV infections are reported in nearly 40 countries (e.g. Singapore and Italy), in
many of which the virus has now become endemic.6 In 2008, the virus was listed as a category C priority

pathogen by the US National Institute of Allergy and Infectious Diseases (NIAID) due to its high morbidity
rate and major health impact.7,8
The symptoms of CHIKV infection generally start 4-7 days after the mosquito bite. The course of infection
typically has two phases, the first acute phase lasting between 1-10 days, characterized by a painful
polyarthralgia, high fever, headache, vomiting, rash, and myalgia. The second is the persistent or chronic
phase with disabling polyarthralgia that can last from weeks to years.9,10 During the recent epidemics,
neurological disorders such as encephalitis, peripheral neuropathy and myelopathy have been reported.11
Cases of multi-organ failure have also been documented12, and eye infections which may cause neuro
retinitis.13,14 CHIKV-induced mortality is limited (1:1000), with most deaths occurring in neonates, the
elderly, and patients with underlying health conditions.
Despite the vast impact of CHIKV infection, a vaccine is still not available. Currently, the treatment
options are limited to symptomatic remedies with e.g. corticosteroids as no antiviral drug is yet
available.15,16 The development of a chemotherapeutic strategy is considered to be as equally important as
the development of a vaccine. In the past years, CHIKV attracted attention from the scientific community
following the elucidation of the structure of the viral protease17 and the viral envelope proteins.18-20 These
reports were followed by in silico structure-based drug design efforts to develop small-molecule
inhibitors.21-25 However, only a few lead compounds with acceptable activity have been reported so far.26
These include mycophenolic acid (MPA 1),27 harringtonine 21,28 and 12-O-tetradecanoylphorbol 13-acetate
(TPA, 3, Figure 1).29 TPA 3 has been reported as the most potent compound with an EC50 = 0.0029 µM and
SI = 1965. However, it is also one of the most potent tumour-promoting agents known to date,19 and
therefore is less likely to be further developed as possible antiviral drug. Harringtonine 2 is a natural
product with a complex chemical structure, which complicates further development, however MPA 1, is a
low molecular weight inhibitor and presents as an excellent candidate for further exploration.

Figure 1 Chemical structure of anti-CHIKV lead compounds with promising antiviral activity.
MPA 1 was reported to inhibit CHIKV replication and virus-induced cell death with an EC50 value of 0.2
µM and a selectivity index value of 150,27 and was found to induce CHIKV apoptosis. It inhibits the
cellular inosine monophosphate dehydrogenase (IMPDH), an enzyme that involved in the de novo

biosynthesis of guanine nucleotide. It is well known that MPA 1 suffers from a metabolic drawback: rapid
conjugation of the C7 phenolic hydroxyl group with glucuronic acid results in more soluble metabolites
that are more easily cleared.20,31-32 Despite this property, MPA 1 is a relatively small molecule with
numerous positions available for modification, including the removal or substitution of the phenolic
hydroxyl group. This study describes the exploration of MPA 1 as a starting point for the development of
compounds with putative anti-CHIKV activity.
Results and Discussions
Design of MPA analogues:
MPA 1 has good drug-like properties with a molecular weight of 320.3, a calculated logP (clogP) value of
2.92, and a calculated logD value of 3.56 (pH = 1-2), 0.67 (pH = 7.4) and 2.52 (pH = 5.5), indicating good
blood solubility and oral bioavailability - oral drug absorption occurs in the small intestine (pH ~ 5.533,34).
Derivatives of MPA 1, in particular those for which the metabolic drawbacks are overcome, could possibly
lead to an antiviral treatment for CHIKV infection.
MPA 1 can be considered as being composed of three connected moieties (Figure 2): an aromatic head (the
3-oxo-1,3-dihydroisobenzofuran moiety), a rigid linker (the alkene connection) and an acidic tail (the
carboxylic acid group). The aromatic head carries two major hydrogen bond acceptors (the carbonyl group
and the oxygen atom of the lactone ring). The aromatic benzo moiety carries a hydroxyl group, a methoxy
group and a methyl group. In this study, the three components of MPA 1 were investigated as optimizable
components, starting from simple core units such as benzoic acids and anilines; Figure 2 shows the possible
access to MPA 1 analogues starting from such derivatives. Both the acids and anilines could be converted
into the aromatic heads carrying H-bond acceptor features, which could be connected through simple C-C
coupling, to the linker and the acidic tail. R groups on the acids and anilines were selected to give similar
environment as in 1.

Figure 2. Design of MPA 1 analogues starting from benzoic acids and aniline derivatives. The red circles
indicate the HB accepting groups, the blue boxes indicate the rigid linker and the green circle refers to the
acidic tail moiety that could be either COOH or the bioisostere tetrazole.
In addition to benzolactones, isatins were also selected as alternative possible replacements for the aromatic
head, as they are known to possess various pharmacological properties including anticholinesterase,
anticonvulsant, antiinflammatory, antihypertensive, antihypoxic, antimicrobial, and antiviral properties.35,36
The structure of isatin could participate in the biological activity, with the two carbonyl groups (red circles,
Figure 2) accepting H-bonds from the target receptor residues, and the NH donating a H-bond to acceptor
residues.37,38 The aromatic core π-system of isatin was also found to participate through aromatic
interactions with some target receptor residues.39
Replacing the rigid linker alkene with the phenyl ring (blue boxes, Figure 2) would be an applicable
strategy for obtaining an analogous linker between the aromatic head and the acidic tail of MPA analogues.
Utilizing cross coupling chemistry40-42 would facilitate facile access to the bi-aromatic system. This phenyl
aromatic linker may also provide a π-electron system for interaction within the yet unknown target site. The
acidic tail remained either as a carboxylic group or the bioisostere tetrazole43 (green, Figure 2). Tetrazole
rings have ionisable acidic proton at pH 7.4. They are also planar in structure, and the anion is 10 times44
more lipophilic than the carboxylate anion and this can enhance drug absorption as a result. Tetrazole rings
are also resistant to many of the metabolic reactions that occur to the carboxylic groups.44,45
Chemistry:
Synthesis of the aromatic heads:
The benzolactone aromatic head synthesis was achieved via Pd catalysed chemistry46 from benzoic acids
using dibromomethane as the solvent and carbon donor (Scheme 1). The Br substituent is prepositioned at
the benzolactone C6 in preparation for metal catalysed cross coupling.

Scheme 1. The synthesis of the benzolactone aromatic heads.
The synthesis of an amino substituted benzolactone was attempted using 2-amino-3-bromo-5methylbenzoic acid 11, which then cyclised to afford the aminobenzolactone 14 (Scheme 2).
Unsurprisingly, the amino-protected compound 13 was not formed, instead, the β-lactam product 12 was
obtained which was then incorporated into the project as an alternative aromatic head.

Scheme 2 The designed synthesis of the aminobenzolactone 14.
The isatin aromatic heads 16 and 25 were formed by reaction with oxalyl chloride (Scheme 3), followed by
the insertion of the C5 bromo substituent using either NBS, or Br2 in acetic acid producing 17 and 26
respectively. The 7-Me substituted isatin 20 was produced from the aniline 18 with the coupling handle
(Br) already in place, using 2,2,2-trichloroethane-1,1-diol and hydroxylamine. These derivatives were
selected to demonstrate similarity to the lead MPA 1, with the OH group masked as methoxy groups to
avoid the metabolic liability.
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Scheme 3. The synthesis of the isatin aromatic heads.

Synthesis of the acid conjugates:
The benzolactone-acid, isatin-acid and β-lactam-acid conjugate syntheses were achieved through the one
step C-C cross coupling reaction with the commercially available 3-(3-boronophenyl)propanoic acid 27
(Scheme 4). This facile one step synthesis gave the three main components of the MPA designed
analogues, the aromatic head, the rigid linker (phenyl) and the acidic tail (COOH).
Synthesis of the tetrazole conjugates:
Tetrazole conjugates were synthesised from acetonitrile intermediates via 3-(3-boronophenyl)propanoic
acid 39 in a coupling reaction with the bromobenzolactones. Due to the high cost of 39, the ester 40 was
also synthesized by reacting 3-iodophenol with 2-chloroacetonitrile, followed by a borylation reaction
(Scheme 5).

Scheme 4. The synthesis of the acid conjugates.

Scheme 5. The synthesis of the boronic ester 40.
The benzolactone-acetonitrile intermediates 44 and 45 were accessed via Suzuki coupling with 39 or 40
(Scheme 6). Subsequent [2 + 3] cycloaddition reaction using NaN3/NH4Cl in DMF afforded the tetrazoles
46 and 47 (Scheme 6).
The modest yields (35%) of the tetrazole formation (Scheme 6) were considered insufficient to justify the
synthesis of further benzolactone-tetrazole conjugates. An alternative synthetic strategy was devised in

which the tetrazole moiety was attached to the boronic ester, prior to the coupling reaction with the 6bromobenzolactones. The previously synthesized 2-(3-iodophenoxy)acetonitrile 42 was used to access the
intermediate 48 utilizing the azide tetrazole formation via mixing with NaN3 and NH4Cl in DMF containing
few drops of glacial acetic acid (Scheme 7). The tetrazole 48 was then reacted with bis(pinacolato)diboron
43, potassium acetate and PdCl2(dppf) catalyst in THF (Scheme 7) to afford the tetrazole salt intermediate
49. The tetrazole conjugates 50 and 51 were synthesized via Suzuki reaction of the tetrazole salt 49 with the
remaining 6-bromobenzolactones (Scheme 7).

Scheme 6. The synthesis of the tetrazole conjugates 46 and 47.

Scheme 7. The synthesis of the tetrazole salt intermediate 49.
The isatin-acetonitrile intermediates were also accessed through the reaction with 39 (Scheme 8), however,
the subsequent [2 + 3] cycloaddition, to form the isatin-tetrazole conjugates, was not successful. The
reaction resulted in the disappearance of all starting materials but produced un-identifiable degradation
products possibly arising both from the reactivity of isatin core and the interference with the cycloaddition
reaction.

Scheme 8. The synthesis of the isatin-acetonitrile intermediates and subsequent attempt to synthesize the
isatin-tetrazole conjugates.
Coupling of the β-lactam intermediate 12 with the boronic ester 40 (Scheme 9) formed the biaryl with
concurrent β-lactam opening to give the benzoic acid derivative 59. The difference between the reaction to
give 38 (Scheme 4) and that to give 59 (Scheme 9) was the workup, with the former quenched at 0 °C
compared to room temperature in the case of 59. It is believed that during this thermally uncontrolled
procedure, the β-lactam ring was hydrolysed to provide the COOH moiety.

Scheme 9. The coupling reaction of the β-lactam 12 with 40.
Antiviral evaluation
All compounds were evaluated for antiviral activity in a virus-cell-based assay against Chikungunya virus
(Indian Ocean strain 899) (Table 1). Compounds for which an EC50 value could be calculated from the
antiviral dose-response curve, were subjected to a similar experiment on treated, uninfected cells to assess
the effect of the compound on host cell metabolism and to determine its selectivity.
Overall, few compounds elicited an antiviral effect in this assay, and the compounds that did, only showed
a limited selectivity (EC50/CC50). Furthermore, microscopic inspection of the assay conditions at which
some inhibition of virus-induced cell death was detected by the MTS/PMS readout method revealed that
none of the compounds matched the hit selection criteria (100% inhibition of virus-induced cell death
without any apparent change in host cell or monolayer morphology). Therefore, none of these compounds
could be considered to be selective inhibitors of CHIKV replication.

This surprising lack of activity for all our synthesized analogues turned our attention back to the original
lead compound MPA 1, questioning the reported activity against CHIKV. Therefore, in order to test the
accuracy of the original finding, we purchased and retested MPA 1, and subjected it to the same antiCHIKV assay. To our dismay, it also came up as being not active (Table 1).
In order to reason these outcomes, we examined the assay conditions described in the original manuscript
that defined MPA as an anti-CHIKV agent. The reported incubation time of the assays was restricted to 48
Table 1. Antiviral activity of compounds in a virus-cell-based assay against Chikungunya virus (strain
899).
Compound

EC50 (µM)

CC50 (µM)

1

11 ± 1

28 ± 10

29

NA

ND

30

NA

ND

31

NA

ND

32

NA

ND

34

NA

ND

35

NA

ND

36

NA

ND

37

NA

ND

38

NA

ND

44

NA

ND

45

NA

ND

46

NA

ND

47

NA

ND

50

NA

ND

51

NA

ND

53

84 ± 14

88 ± 18

54

NA

ND

55

NA

ND

59

NA

ND

NA = not active; ND = not determined; EC50 = concentration of compound that inhibits virus-induced cell
death with 50%; CC50 = concentration of compound that reduces the metabolic activity of treated,
uninfected cells with 50%; results are reported as median and standard deviation from a series of at least 2
independent experiments.

hours – in this scenario, MPA reduces the GTP concentration, and as CHIKV replicates much slower, it has
not had the opportunity to kill the cells at this 48 hours post-infection timepoint. If a compound is a true
antiviral, then it should show antiviral activity even five days post-infection. Therefore, in Chikungunya
antiviral testing, it is imperative to incubate the assay for five days to allow sufficient time to show a timedependency of the antiviral effect. In our five-day anti-CHIKV assays, we have shown that there is no
lasting antiviral effect of MPA against CHIKV. Therefore, MPA is likely a 'braking' compound, applying
the ‘brakes’ on the replication of CHIKV, but not completely stopping it from multiplying. Therefore, MPA
1 cannot be considered a lead compound targeting the CHIKV and must be reassessed as a lead compound.
Conclusions
To summarize, using MPA as a lead compound for the design and synthesis of potential compounds
targeting the CHIKV, we synthesized a series of isatin and bezolactone derivatives. Subsequent testing
revealed no activity which led to retesting of the lead MPA 1. We found that it did not possess any antiCHIKV activity and therefore we conclude that it cannot be considered as an inhibitor of CHIKV.
Experimental section
Chemical synthesis
Unless

otherwise

stated,

chemicals

were

purchased

from

Sigma

Aldrich

(Australia).

(Cyanomethoxy)phenyl)boronic acid was purchased from Combi-Blocks, Inc., USA. All 1H,

13

(3-

C and

spectra were recorded at 500 and 125 MHz, respectively on a Varian Inova 500 MHz spectrometer.
Chemical shifts (δ) are reported in parts per million relative to TMS using CDCl3 as a solvent unless
otherwise noted. The solvents used for

13

C NMR were the same used for the 1H NMR unless otherwise

noted. Coupling constants (J) are reported in Hertz (Hz). Multiplicities are reported as singlet (s), broad
(br), doublet (d), doublet of doublets (dd), doublet of doublets of doublets (ddd), doublet of triplet (dt),
multiplet (m), pentet (p), sextet (sex) or septet (sp). Electron impact (EI) and electrospray (ES) mass spectra
(MS) were recorded on a Shimadzu QP-5000 spectrometer and high resolution (HR) on a VG AutoSpec
spectrometer. Electrospray (ESI) mass spectra were recorded on a Micromass Platform LCZ spectrometer
and high resolution on a Micromass QTOF2 spectrometer. Ion mass to charge (m/z) values are stated with
their relative abundances as a percentage in parentheses. Peaks assigned to the molecular ion are denoted
by M+ or M- (when using the ESI-). Thin Layer Chromatography (TLC) was performed using Merck Silica
Gel F254 aluminium sheets. Column chromatography purifications were performed using Flash Silica Gel.
Infrared (IR) spectra were recorded on a (Shimadzu FT-IR spectrometer) fitted with a Smart Omni-Sampler
germanium crystal accessory. All IR spectra were recorded on neat samples with strong, medium and weak
peaks are assigned as s, m and w, respectively. Melting points were determined using a Gallenkamp
(Griffin) melting point apparatus. Temperatures are expressed in degrees Celsius (ºC) and are uncorrected.
HPLC purity check was performed using Waters 1525 HPLC pump, WatersTm 486 absorbance detector
(using the wavelength, 254 nm) and Nova-Pak® Silica 3.9 x 150 mm C18 column. HPLC solvents used:

solvent A hexane, solvent B isopropanol containing 0.1% TFA and solvent C isopropanol. Retention times
in minutes for the HPLC results are expressed as Rt.
General procedure 1: synthesis of the isobenzofuran-1(3H)-ones (7-10)
Under a N2 atmosphere, a sealed tube was charged with the appropriate benzoic acid (1 mmol), palladium
acetate (22.4 mg, 0.1 mmol), dipotassium phosphate (K2HPO4, 522.5 mg, 3 mmol) and dibromomethane (4
mL). The contents of the tube were degassed by flushing N2 through a needle for 10 min. The tube was then
sealed, and heated in an oil bath at 140 ºC for 36 h. The tube was then allowed to cool to room temperature,
the content was diluted with CH2Cl2 (20 mL), and filtered through celite. The filtrate was washed with 1 M
HCl (20 mL) and brine (2 x 15 mL), and was dried (MgSO4). The solvent was evaporated under reduced
pressure and the residue was either subjected to flash column chromatography (10% methanol in
chloroform) or recrystallised from chloroform/hexane mixture (1:3).
6-Bromo-7-methoxyisobenzofuran-1(3H)-one (7)
Following the general procedure 1 using 3-bromo-2-methoxybenzoic acid 4 (231 mg), the benzofuran 7
was isolated after column chromatography, as a white solid (92 mg, 38%), mp: 102-103 ºC; IR (cm-1): υ
1752 (s, C=O), 1288 (m, C-O), 1064 (w, C-O), 1111 (w, C-Br). 1H NMR (CDCl3), δ: 7.84 (d, J = 7.9 Hz,
1H, H5), 7.06 (d, J = 7.9 Hz, 1H, H4), 5.23 (s, 2H, CH2), 4.16 (s, 3H, OCH3). 13C NMR, δ: 167.5 (C=O),
156.3 (C7), 148.3 (C3a), 139.3 (C5), 118.6 (C4), 117.9 (C7a), 117.2 (C6), 68.7 (CH2), 62.9 (CH3) ppm. EIMS m/z 244 (M+ 81Br, 28), 242 (M+ 79Br, 30), 215 (31), 213 (33), 198 (100%), 196 (98), 185 (17), 183 (15).
HRMS (ESI) calcd for C9H879BrO3 (MH+), 242.9649; found, 242.9657.
6-Bromo-7-methylisobenzofuran-1(3H)-one (8)
Following the general procedure 1 using 3-bromo-2-methylbenzoic acid 5 (215 mg), the benzofuran 8 was
isolated after recrystallisation, as a pale yellow solid (124 mg, 55%), mp: 91-92 ºC; IR (cm-1): υ 1739 (s,
C=O), 1358 (w, C-O), 1069 (w, C-Br). 1H NMR (CDCl3), δ: 7.79 (d, J = 8.0 Hz, 1H, H5), 7.18 (d, J = 8.0
Hz, 1H, H4), 5.20 (s, 2H, CH2), 2.74 (s, 3H, CH3).

13

C NMR, δ: 170.1 (C=O), 146.1 (C3a), 139.8 (C5),

137.7 (C4), 126.3 (C7), 124.7 (C7a), 120.6 (C6), 68.2 (CH2), 16.6 (CH3) ppm. EI-MS m/z 228 (M+
54), 226 (M+

79

81

Br,

Br, 55), 199 (100%), 197 (99), 171 (32), 169 (30). HRMS (ESI) calcd for C9H879BrO2

(MH+), 226.9708; found, 226.9705.
5,7-Dimethoxyisobenzofuran-1(3H)-one 4 1 (9)
Following the general procedure 1 using 2,4-dimethoxybenzoic acid 6 (182 mg). The benzofuran 9 was
isolated after column chromatography as a white solid (112.5 mg, 58%). Spectral data of the isolated
benzofuran 9 are in agreement with that reported.41
6-Bromo-5,7-dimethoxyisobenzofuran-1(3H)-one (10)
In a round bottom flask (50 mL), 5,7-dimethoxyisobenzofuran-1(3H)-one 9 (150 mg, 0.773 mmol) was
dissolved in glacial acetic acid (20 mL) with vigorous stirring and the flask was cooled to -5 - 0 ºC using an

ice bath. A solution of bromine (136 mg, 0.851 mmol) in glacial acetic acid (10 mL) was added dropwise
over 20 min. The reaction was allowed to warm up slowly to room temperature and was then allowed to stir
for 4 h. The formed solid was filtered and washed with dilute acetic acid, and was then subjected to column
chromatography (60% CH2Cl2 in hexane) to afford the benzofuran 10 (176.7 mg, 84%) as a white solid. It
could also be recrystallised from 1,4-dioxane, mp: 189-190 ºC; IR (cm-1): υ 1700 (s, C=O), 1316 (w, C-O),
1071 (w, C-O), 1036 (w, C-Br). 1H NMR (CDCl3), δ: 6.46 (s, 1H, H4), 5.07 (s, 2H, CH2), 4.02 (s, 6H,
OCH3). 13C NMR, δ: 168.4 (C=O), 162.2 (C7), 159.5 (C5), 150.5 (C3a), 107.8 (C7a), 96.2 (C6), 95.1 (C4),
69.3 (CH2), 57.1 (C7-OCH3), 56.6 (C5-OCH3) ppm. EI-MS m/z 274 (M+ 81Br, 38), 272 (M+ 79Br, 40), 256
(18), 254 (20), 245 (32), 243 (30), 228 (100%), 226 (100), 215 (20), 213 (21). HRMS (ESI) calcd for
C10H1079BrO4 (MH+), 272.9762; found, 272.9754.
6-Bromoisobenzofuran-1(3H)-one (28)
This compound was prepared according to reported procedures.42
5-Bromo-3-methyl-7-pivaloyl-7-azabicyclo[4.2.0] octa-1,3,5-trien-8-one (12)
In an oven dried 50 mL flask and under a N2 atmosphere, 2-amino-3-bromo-5-methylbenzoic acid 11 (750
mg, 3.26 mmol) was dissolved in dry THF (20 mL), and the flask was then sealed with a rubber cap with
fitted with a N2 balloon, and cooled to -78 ºC. n-BuLi (4.08 mL of 2 M solution, 8.15 mmol) was added
dropwise through a needle and the mixture was stirred for 20 min at -78 ºC before adding pivaloyl chloride
(0.48 mL, 3.91 mmol) dropwise. The reaction was then allowed to warm to room temperature and stirred
for 3 h. The reaction mixture was then diluted with ethyl acetate (10 mL) and water (10 mL), the organic
layer was separated and washed with water (2 x 20 mL), brine (2 x 10 mL) and dried (MgSO4). The
combined organic layers were concentrated under reduced pressure to yield the β-lactam derivative 12 as a
colourless oil (452 mg, 47%), IR (cm-1): υ 1745 (s, C=O), 1634 (s, C=O), 1465 (w, C-N), 1059 (w, C-Br).
1

H NMR (CDCl3), δ: 7.94 (s, 1H, H4), 7.86 (s, 1H, H2), 2.45 (s, 3H, CH3), 1.42 (s, 9H, pivaloyl 3xCH3).

13

C NMR, δ: 168.1 (pivaloyl C=O), 159.7 (C6), 142.3 (C=O), 140.9 (C4), 139.3 (C1), 127.4 (C2), 121.8

(C3), 117.8 (C5), 38.3 (C(CH3)3), 27.6 (pivaloyl 3xCH3), 20.9 (CH3) ppm. EI-MS m/z 297 (M+, 81Br, 33),
295 (M+,

79

Br, 35), 282 (98), 280 (100%), 255 (18), 253 (20), 240 (35), 238 (37). HRMS (ESI) calcd for

C13H15BrNO2 (MH+), 296.0286; found, 296.0294.
4,6-Dimethoxyindoline-2,3-dione 4 3 (16)
This compound was prepared following the reported procedure.43 The 4,6-dimethoxyindole-2,3-dione 16
was obtained as a yellow solid (5.2 g, 80%).
5-Bromo-4,6-dimethoxyindoline-2,3-dione (17)
In a 100 mL round bottom flask, a solution of 4,6-dimethoxyindole-2,3-dione 16 (143 mg, 0.5 mmol) in
acetic acid (10 mL) was stirred at room temperature until all the isatin was completely dissolved before
being cooled to 0 ºC using an ice bath. N-Bromosuccinimide (97.9 mg, 0.55 mmol) was added portion wise

over 15 min. After addition of the NBS, the reaction mixture started to solidify, and the flask was removed
from the ice bath and was allowed to warm to room temperature and then stirred for 8 h. The yellow solid
was filtered from the mother liquor to which cold water (10 mL) was added to precipitate the remaining
soluble product. The combined solids were washed with saturated NaHCO3 solution (2 x 15 mL) and with
1:1 water ethanol mixture (25 mL) and then vacuum dried. Recrystallisation from 1,4-dioxane yielded the
5-bromo-4,6-dimethoxyindoline-2,3-dione 17 as a yellow solid (118 mg, 60%), mp: >250 ºC; IR (cm-1): υ
3195 (m, NH), 1718 (s, C=O), 1264 (m, C-O). 1H NMR (DMSO-d6), δ: 11.14 (s, NH), 6.36 (s, H7), 3.99 (s,
3H, C6-OCH3), 3.94 (s, 3H, C4-OCH3). 13C NMR, δ: 178.4 (C3), 165.5 (C2), 161.7 (C4), 160.4 (C6), 151.4
(C7a), 102.7 (C3a), 91.8 (C7), 86.2 (C5), 58.1 (C4-OCH3), 57.2 (C6-OCH3) ppm. EI-MS m/z 287 (M+ 81Br,
40), 285 (M+
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Br, 42), 259 (98), 257 (100%), 215 (6), 213 (7). HRMS (ESI) calcd for C10H9N79BrNO4

(MH+), 285.9715; found, 285.9719.
5-Bromo-7-methylindoline-2,3-dione 4 4 (20)
4-Bromo-2-methylaniline 18 (6.88 g, 37 mmol) was added to a 500 mL flask and was reacted with chloral
hydrate (7.35 g, 44.4 mmol), hydroxylamine hydrochloride (9.25 g, 133 mmol), sodium sulfate (42 g, 295
mmol) in water (250 mL) and 2 M HCl (12.5 mL), by heating the mixture at 55 ºC with vigorous stirring
for 14 h. After cooling to room temperature, the aqueous layer was decanted from the formed gummy
residue which was further washed with cold water and dried under vacuum. The flask was then cooled to -5
- 0 ºC using ice/salt bath before adding cold sulfuric acid (22.5 mL). The flask was allowed to warm to
room temperature before heating the reaction mixture gradually to 70 ºC where the mixture started to get
darker in colour. When the colour change became stable after almost 30 min, the reaction was heated to 80
ºC for 10 min. After cooling to room temperature, the mixture was poured onto crushed ice (150 mL) and
stirred for 1 h. The separated solid was then filtered and washed with water (3 x 100 mL) to give a red solid
of 5-bromo-7-methylindoline-2,3-dione 20 (6.65 g, 75%) and was sufficiently pure for the next step. The
spectral data were consistent with the reported literature.44
4-Methoxy-1-methyl-2-nitrobenzene 4 5 (22)
This compound was synthesized following the reported procedure from 4-methyl-3-nitrophenol 21.45 The
4-methoxy-1-methyl-2-nitrobenzene 22 was isolated as a white crystalline solid (5.34 g, 80%).
5-Methoxy-2-methylaniline 4 6 (23)
To a solution of 4-methoxy-1-methyl-2-nitrobenzene 22 (5.1 g, 30.5 mmol) in methanol (35 mL) under a
N2 atmosphere was added Raney Nickel (0.1 mol %) and the mixture was vigorously stirred at room
temperature until the H2 ceased to evolve. Hydrazine monohydrate (2.0 g, 41 mmol) in methanol (10 mL)
was added through a syringe slowly over 10 min. The mixture was then heated at reflux for 4 h. The
reaction mixture was filtered hot through celite, and the filtrate was concentrated under reduced pressure.
The obtained residue was recrystallised from petroleum spirit to yield 5-methoxy-2-methylaniline 23 as

white solid (3.8 g, 91%). Spectral data for this aniline derivative 23 were in agreement with the reported
literature.46
4-Methoxy-7-methylindoline-2,3-dione (25)
In a 250 mL round bottom flask, 5-methoxy-2-methylaniline 23 (2.0 g, 15 mmol) was dissolved in
anhydrous benzene (20 mL), and oxalyl chloride (4.12 g, 2.8 mL, 32.4 mmol) was added dropwise. When
the HCl ceased to evolve, the reaction was heated at reflux for 3 h. The benzene and oxalyl chloride were
then removed by distillation, and the residue was quickly suspended in dichloroethane (20 mL) and then
cooled to 0 ºC in an ice bath. Aluminium chloride (2.1 g, 15.5 mmol) as a suspension in dichloroethane (10
mL) was added portion wise with vigorous stirring and the reaction mixture was allowed to warm to room
temperature over 3 h. The reaction mixture was then heated at reflux for 40 min. After cooling to room
temperature, the mixture was poured onto crushed ice, portioned between 0.1 M HCl and ethyl actetate.
The aqueous layer was further extracted with ethyl acetate (2 x 100 mL). The combined organic layers were
washed with brine (100 mL), dried (MgSO4) and evaporated under reduced pressure. The resulting orange
solid was subjected to a flash column chromatography and elution with 30% ethyl acetate in petroleum
spirit yielded 4-methoxy-7-methylindoline-2,3-dione 25 as an orange solid (0.84 g, 30%), mp: 235-236 ºC;
IR (cm-1): υ 3195 (m, NH), 1635 (s, C=O), 1250 (m, C-O). 1H NMR (DMSO-d6), δ: 10.99 (s, NH), 7.36 (d,
J = 8.7, 1H, H6), 6.61 (d, J = 8.7, 1H, H5), 3.83 (s, 3H, OCH3), 2.09 (s, 3H, CH3). 13C NMR, δ: 180.9 (C2),
160.1 (C3), 156.4 (C4), 149.1 (C7a), 141.8 (C6), 112.9 (C7), 106.5 (C5), 105.8 (C3a), 55.8 (OCH3), 14.6
(CH3) ppm. EI-MS m/z 191 (M+, 100%), 163 (50), 149 (10), 134 (7), 121 (7), 106 (93). HRMS (ESI) calcd
for C10H12NO3 (MH+), 192.0661; found, 192.0653.
5-Bromo-4-methoxy-7-methylindoline-2,3-dione (26)
In a 100 mL round bottom flask, 4-methoxy-7-methylindoline-2,3-dione 25 (440 mg, 2.3 mmol) was
dissolved in glacial acetic acid (15 mL) and the mixture was stirred until the solid dissolved completely.
The flask was then cooled to 0 ºC using an ice bath. A solution of bromine (405 mg, 2.5 mmol) in glacial
acetic acid (5 mL) was then added dropwise over 10 min. The flask was allowed to warm to room
temperature and was stirred for 2 h. The resulting solid was filtered and cold water (15 mL) added to the
filtrate and the resulting solid was filtered. The combined solids were washed with saturated NaHCO3 (2 x
25 mL) and water (2 x 25 mL), and recrystallised from acetic acid to yield 5-bromo-4-methoxy-7methylindoline-2,3-dione 26 as an orange solid (520.5 mg, 84%), mp: >250 ºC; IR (cm-1): υ 3162 (m, NH),
1696 (s, C=O), 1248 (w, C-O). 1H NMR (DMSO-d6), δ: 11.20 (s, NH), 7.67 (s, H6), 3.97 (s, 3H, OCH3),
2.12 (s, 3H, CH3).
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C NMR, δ: 180.7 (C2), 159.2 (C3), 152.6 (C4), 148.9 (C7a), 142.6 (C6), 117.7 (C7),

110.1 (C3a), 108.1 (C5), 61.8 (OCH3), 14.6 (CH3) ppm. EI-MS m/z 271 (M+ 81Br, 90), 269 (M+ 79Br, 92),
243 (98), 241 (100%), 228 (20), 226 (21), 185 (80). HRMS (ESI) calcd for C10H979BrNO3 (MH+),
269.9766; found, 269.9773.

General procedure 2: Suzuki coupling of 6-bromobenzolactone derivatives 7, 8, 10 and
28 with 3-(3-boronophenyl)propanoic acid 27
Under a N2 atmosphere, a 25 mL flask was charged with the bromoisobenzofuran-1(3H)-one (1 equiv), 3(3-boronophenyl)propanoic acid 27 (1.2 equiv), tetrakis(triphenylphosphine)palladium(0) (5 mol%) and
1,4-dioxane (5 mL). The flask was sealed with a rubber cap. The reaction mixture was degassed by flushing
N2 through a needle for 10 min. The flask was heated in an oil bath at 85 ºC. When the solid dissolved, a N2
degassed solution of potassium phosphate (3 equiv) in water (3 mL) was added to the reaction mixture and
heating at 85 ºC continued for 4-6 h. After cooling to room temperature, the solvent was concentrated under
reduced pressure, and 2 M HCl (15 mL) was added to the residue. The suspended solid was either collected
by filtration or extracted with ethyl acetate (2 x 25 mL). The combined ethyl acetate extracts were dried
(MgSO4) and evaporated under reduced pressure. The obtained residues were dissolved in ethanol and were
subjected to PLC (10% methanol in CH2Cl2, 0.5% acetic acid).
3-(3-(4-Methoxy-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid (29)
Following the general procedure 2 using 6-bromo-7-methoxyisobenzofuran-1(3H)-one 7 (110 mg, 0.453
mmol),

3-(3-boronophenyl)propanoic

acid

27

(105.5

mg,

0.544

mmol),

tetrakis(triphenylphosphine)palladium(0) (26.2 mg, 0.023 mmol) and potassium phosphate (288.5 mg,
1.359 mmol) and heating for 5 h, the acid 29 was isolated as a white solid (87.5 mg, 62%), mp: 116-117
ºC; IR (cm-1): υ 2989 (m, OH), 1755 (s, C=O), 1718 (s, C=O), 1216 (m, C-O). 1H NMR (acetone-d6), δ:
10.54 (bs, 1H, COOH), 7.73 (d, 1H, J = 7.5 Hz, isobenzofuran_6H), 7.45 (s, 1H, phenyl_2H), 7.41 (d, 1H,
J = 7.7 Hz, phenyl_4H), 7.40-7.37 (m, 2H, phenyl_5,6 H), 7.30 (d, 1H, J = 7.5 Hz, isobenzofuran_7 H),
5.37 (s, 2H, isobenzofuran CH2), 3.88 (s, 3H, OCH3), 2.99 (t, 2H, J = 6.7 Hz, COOH-CH2-CH2), 2.68 (t,
2H, J = 6.7 Hz, COOH-CH2-CH2).
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C NMR (CDCl3), δ: resonance attributed to COOH not observed,

168.9 (C=O), 156.9 (isobenzofuran C4), 148.4 (phenyl C1), 140.5 (isobenzofuran C7a), 137.8 (phenyl C5),
137.1 (isobenzofuran C6), 135.7 (phenyl C6), 129.5 (phenyl C3), 128.7 (phenyl C2), 127.9 (isobenzofuran
C5), 127.5 (phenyl C4), 118.0 (isobenzofuran C3a), 117.1 (isobenzofuran C7), 68.9 (isobenzofuran C1),
62.7 (OCH3), 47.4 (COOH-CH2-CH2), 30.8 (COOH-CH2-CH2) ppm. EI-MS m/z 312 (M+, 75), 295 (20),
266 (17), 239 (100%), 223 (50), 208 (15), 195 (51). HRMS (ESI) calcd for C18H17O5 (MH+), 313.1076;
found, 313.1078. HPLC purity: 97.4%, Rt=8.245 (1% solvent B in solvent A).
3-(3-(4-Methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid (30)
Following the general procedure 2 using 6-bromo-7-methylisobenzofuran-1(3H)-one 8 (95 mg, 0.418
mmol),

3-(3-boronophenyl)propanoic

acid

27

(97.3

mg,

0.502

mmol),

tetrakis(triphenylphosphine)palladium(0) (24.2 mg, 0.021 mmol) and potassium phosphate (266.2 mg,
1.254 mmol) and heating for 4 h, the acid 30 was isolated as a white solid (66.8 mg, 54%), mp: 110-111 ºC;
IR (cm-1): υ 2989 (m, OH), 1731 (s, C=O), 1696 (s, C=O). 1H NMR (CDCl3), δ: 7.55 (d, 1H, J = 7.8 Hz,
isobenzofuran_6 H), 7.50 (d, 1H, J = 7.3 Hz, phenyl_4 H), 7.37 (t, 1H, J = 7.3 Hz, phenyl_5 H), 7.26 (d,

1H, J = 7.3 Hz, phenyl_6 H), 7.20 (s, 1H, phenyl_2 H), 7.16 (d, 1H, J = 7.3 Hz, isobenzofuran_7 H), 5.28
(s, 2H, isobenzofuran CH2), 3.02 (t, 2H, J = 7.3 Hz, COOH-CH2-CH2), 2.74 (t, 2H, J = 7.3 Hz, COOHCH2-CH2), 2.59 (s, 3H, CH3).

13

C NMR, δ: resonance attributed to COOH not observed, 171.6 (C=O),

146.3 (phenyl C1), 143.5 (isobenzofuran C7a), 140.5 (phenyl C3), 140.3 (isobenzofuran C4), 137.6 (phenyl
C2), 135.7 (isobenzofuran C5), 132.3 (phenyl C5), 129.5 (phenyl C6), 128.7 (isobenzofuran C6), 127.6
(phenyl C4), 123.8 (isobenzofuran C3a), 119.1 (isobenzofuran C7), 68.5 (isobenzofuran C1), 35.7 (COOHCH2-CH2), 30.7 (COOH-CH2-CH2), 14.9 (CH3) ppm. EI-MS m/z 296 (M+, 100%), 278 (54), 260 (46), 250
(80), 136 (60), 223 (40). HRMS (ESI) calcd for C18H17O4 (MH+), 297.1127; found, 297.1129. HPLC
purity: 97.9%, Rt=5.571 (1% solvent B in solvent A).
3-(3-(4,6-Dimethoxy-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid (31)
Following the general procedure 2 using 6-bromo-5,7-dimethoxyisobenzofuran-1(3H)-one 10 (80 mg,
0.293

mmol),

3-(3-boronophenyl)propanoic

acid

27

(68.2

mg,

0.352

mmol),

tetrakis(triphenylphosphine)palladium(0) (16.9 mg, 0.015 mmol) and potassium phosphate (186.6 mg,
0.879 mmol) and heating for 6 h, the acid 31 was isolated as a pale yellow oil (56 mg, 56%), IR (cm-1): υ
2989 (m, OH), 1750 (s, C=O), 1739 (s, C=O), 1208 (w, C-O). 1H NMR (CDCl3), δ: 7.33 (t, 1H, J = 7.9 Hz,
phenyl_5 H), 7.18 (d, 1H, J = 7.9 Hz, phenyl_4 H), 7.12-7.10 (m, 2H, phenyl_2,6 H), 6.50 (s, 1H,
isobenzofuran_7 H), 4.98 (s, 2H, isobenzofuran CH2), 4.03 (s, 3H, isobenzofuran_4 OCH3), 3.85 (s, 3H,
isobenzofuran_6 OCH3), 2.97 (t, 3H, J = 7.6 Hz, COOH-CH2-CH2), 2.66 (t, 3H, J = 7.6 Hz, COOH-CH2CH2).
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C NMR, δ: 177.2 (COOH), 169.0 (C=O), 162.8 (isobenzofuran C6), 159.4 (isobenzofuran C4),

149.3 (phenyl C1), 140.7 (isobenzofuran C7a), 133.8 (phenyl C3), 129.3 (phenyl C2), 128.7 (phenyl C5),
127.7 (phenyl C4), 127.4 (phenyl C6), 117.5 (isobenzofuran C3a), 106.1 (isobenzofuran C5), 95.5
(isobenzofuran C7), 68.3 (isobenzofuran C1), 56.3 (isobenzofuran_6 OCH3), 56.2 (isobenzofuran_4
OCH3), 35.6 (COOH-CH2-CH2), 30.7 (COOH-CH2-CH2) ppm. EI-MS m/z 342 (M+, 100), 326 (25), 296
(26). HRMS (ESI) calcd for C19H18O6 (MH+), 343.1182; found, 343.1190. HPLC purity: 98.7%, Rt=13.234
(5% solvent B in solvent A).
3-(3-(3-Oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid (32)
Following the general procedure 2 using 6-bromoisobenzofuran-1(3H)-one 28 (90 mg, 0.422 mmol), 3-(3boronophenyl)propanoic acid 27 (98.2 mg, 0.506 mmol), tetrakis(triphenylphosphine)palladium(0) (24.4
mg, 0.021 mmol) and potassium phosphate (268.7 mg, 1.266 mmol) and heating for 4 h, the acid 28 was
isolated as a white solid (92.8 mg, 78%), mp: 118-119 ºC; IR (cm-1): υ 2972 (m, OH), 1743 (s, C=O), 1699
(s, C=O). 1H NMR (CDCl3), δ: 8.11 (s, 1H, isobenzofuran_4 H), 7.90 (d, 1H, J = 8.0 Hz, phenyl_4 H), 7.55
(d, 1H, J = 7.9 Hz, phenyl_6 H), 7.47 (s, 1H, phenyl_2 H), 7.46 (d, 1H, J = 6.2 Hz, isobenzofuran_6 H),
7.41 (t, 1H, J = 8.0 Hz, phenyl_5 H), 7.27 (d, 1H, J = 6.7 Hz, isobenzofuran_7 H), 5.37 (s, 2H,
isobenzofuran CH2), 3.05 (t, 2H, J = 7.6 Hz, COOH-CH2-CH2), 2.75 (t, 2H, J = 7.6 Hz, COOH-CH2-CH2).
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C NMR, δ: 178.3 (COOH), 171.4 (C=O), 145.5 (phenyl C1), 142.8 (isobenzofuran C7a), 141.4 (phenyl

C2), 139.9 (isobenzofuran C5), 133.4 (phenyl C3), 129.6 (phenyl C5), 128.3 (phenyl C6), 127.6
(isobenzofuran C6), 126.7 (isobenzofuran C3a), 125.6 (phenyl C4), 124.3 (isobenzofuran C4), 122.7
(isobenzofuran C7), 69.9 (isobenzofuran C1), 35.6 (COOH-CH2-CH2), 30.8 (COOH-CH2-CH2) ppm. EIMS m/z 282 (M+, 70), 253 (20), 237 (100%), 223 (16). HRMS (ESI) calcd for C17H15O4 (MH+), 283.0970;
found, 283.0974. HPLC purity: 99.6%, Rt=6.285 (2% solvent B in solvent A).
General procedure 3: Suzuki coupling of 5-bromoisatin derivatives 17, 20, 26 and 33
with 3-(3-boronophenyl)propanoic acid 27
Under a N2 atmosphere, a 25 mL flask was charged with the 5-bromoisatin derivative (1 equiv), 3-(3boronophenyl)propanoic acid 27 (1.2 equiv), tetrakis(triphenylphosphine)palladium(0) (5 mol%) and DME
(3 mL) or diglyme (3 mL), was sealed with a rubber cap. The reaction mixture was degassed by flushing N2
through a needle for 10 min, and was then heated in an oil bath at 85 ºC. When the solid dissolved, a N2
degassed solution of potassium phosphate (3 equiv) in water (3 mL) was added to the reaction mixture and
heating continued at 85 ºC for 4-6 h. After cooling to room temperature, the solvent was concentrated under
reduced pressure. A solution of HCl 2 M (15 mL) was added, and the resulting suspended solid was either
collected by filtration or extracted with ethyl acetate (2 x 25 mL). The combined organic layers were dried
(MgSO4) and evaporated under reduced pressure. The combined residues were then dissolved in ethanol
and were subjected to PLC (10% methanol in CH2Cl2, 0.5% acetic acid) to yield the isatin-acid conjugates
34-37.
3-(3-(4,6-Dimethoxy-2,3-dioxoindolin-5-yl)phenyl)propanoic acid (34)
Following the general procedure 3 using 5-bromo-4,6-dimethoxyindoline-2,3-dione 17 (100 mg, 0.349
mmol),

3-(3-boronophenyl)propanoic

acid

27

(81.2

mg,

0.419

mmol),

tetrakis(triphenylphosphine)palladium(0) (20.2 mg, 0.017 mmol) and potassium phosphate (222.2 mg,
1.047 mmol) and heating for 6 h, the acid 34 was isolated as a yellow solid (49.5 mg, 40%), mp: 175-176
ºC; IR (cm-1): υ 3185 (m, NH), 2978 (m, OH), 1718 (s, C=O), 1696 (s, C=O), 1290 (w, C-O). 1H NMR
(DMSO-d6), δ: 12.09 (s, 1H, COOH), 10.36 (s, NH), 7.31 (t, J = 7.5 Hz, 1H, phenyl_5 H), 7.20 (d, J = 7.5
Hz, 1H, phenyl_4 H), 7.08-7.06 (m, 2H, phenyl_2,6 H), 6.35 (s, 1H, isatin_7 H), 3.97 (s, 3H, isatin_4
OCH3), 3.84 (s, 3H, isatin_C6 OCH3), 2.85 (t, J = 7.5 Hz, 2H, COOH-CH2-CH2), 2.58 (t, J = 7.5 Hz, 2H,
COOH-CH2-CH2).
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C NMR, δ: 178.1 (COOH), 174.0 (isatin C2), 166.6 (isatin C3), 161.5 (isatin C6),

160.1 (isatin C4), 149.2 (phenyl C1), 141.0 (isatin C7a), 131.2 (phenyl C3), 130.3 (phenyl C5), 128.3
(double height, phenyl C4 and C6), 127.4 (phenyl C2), 108.2 (isatin C7), 100.6 (isatin C5), 90.1 (isatin
C3a), 56.7 (isatin_4 OCH3), 56.3 (isatin_6 OCH3), 35.0 (COOH-CH2-CH2), 30.3 (COOH-CH2-CH2) ppm.
EI-MS m/z 355 (M+, 40), 299 (4), 254 (100%), 191 (45). HRMS (ESI) calcd for C19H18NO6 (MH+),
356.1134; found, 356.1116. HPLC purity: 99.3%, Rt=35.814 (3% solvent B in solvent A).
3-(3-(7-Methyl-2,3-dioxoindolin-5-yl)phenyl)propanoic acid (35)

Following the general procedure 3 using 5-bromo-7-methylindoline-2,3-dione 20 (100 mg, 0.416 mmol), 3(3-boronophenyl)propanoic acid 27 (96.8 mg, 0.499 mmol), tetrakis(triphenylphosphine)palladium(0) (24
mg, 0.021 mmol) and potassium phosphate (264.9 mg, 1.248 mmol) and heating for 4 h, the acid 35 was
isolated as a red solid (70 mg, 55%), mp: 238-239 ºC; IR (cm-1): υ 3172 (m, NH), 2989 (m, OH), 1731 (s,
C=O), 1696 (s, C=O). 1H NMR (acetone-d6), δ: 9.94 (s, NH), 7.81 (s, 1H, isatin_4 H), 7.66 (s, 1H,
phenyl_2 H), 7.60 (s, 1H, isatin_6 H), 7.50 (d, J = 7.6 Hz, 1H, pheny_6 H), 7.40 (t, J = 7.6 Hz, 1H,
phenyl_5 H), 7.29 (d, J = 7.6 Hz, 1H, phenyl_4 H), 3.03 (t, J = 7.3 Hz, 2H, COOH-CH2-CH2), 2.71 (t, J =
7.3 Hz, 2H, COOH-CH2-CH2), 2.41 (s, 3H, CH3).
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C NMR (DMSO-d6), δ: 184.8 (COOH), 173.9 (isatin

C3), 160.1 (isatin C2), 148.5 (isatin C7a), 141.7 (phenyl C3), 138.7 (phenyl C1), 137.6 (isatin C6), 134.8
(isatin C5), 128.9 (phenyl C5), 127.4 (phenyl C6), 126.5 (phenyl C2), 123.8 (phenyl C4), 122.1 (isatin C4),
119.8 (isatin C3a), 118.1 (isatin C7), 35.3 (COOH-CH2-CH2), 30.4 (COOH-CH2-CH2), 15.5 (CH3) ppm. EIMS m/z 309 (M+, 100%), 277 (25), 253 (80), 207 (79), 193 (30). HRMS (ESI) calcd for C18H16NO4 (MH+),
310.1079; found, 310.1071. HPLC purity: 98.1%, Rt=5.339 (1% solvent B in solvent A).
3-(3-(4-Methoxy-7-methyl-2,3-dioxoindolin-5-yl)phenyl) propanoic acid (36)
Following the general procedure 3 using 5-bromo-4-methoxy-7-methylindoline-2,3-dione 26 (100 mg,
0.370

mmol),

3-(3-boronophenyl)propanoic

acid

27

(86.1

mg,

0.444

mmol),

tetrakis(triphenylphosphine)palladium(0) (21.4 mg, 0.019 mmol) and potassium phosphate (235.6 mg, 1.11
mmol) and heating for 5 h, the acid 36 was isolated as a red solid (60 mg, 48%), mp: 219-220 ºC; IR (cm-1):
υ 3182 (m, NH), 2982 (m, OH), 1749 (s, C=O), 1692 (s, C=O), 1287 (w, C-O). 1H NMR (DMSO-d6), δ:
11.16 (s, NH), 7.40 (s, 1H, isatin_6 H), 7.13 (t, J = 7.4 Hz, 1H, phenyl_5 H), 7.26 (s, 1H, phenyl_2 H), 7.22
(d, J = 7.4 Hz, 1H, pheny_6 H), 7.19 (d, J = 7.4 Hz, 1H, phenyl_4 H), 3.81 (s, 3H, OCH3), 2.86 (t, J = 7.4
Hz, 2H, COOH-CH2-CH2), 2.56 (t, J = 7.4 Hz, 2H, COOH-CH2-CH2), 2.41 (s, 3H, CH3).
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C NMR, δ:

182.8 (COOH), 174.5 (isatin C2), 160.5 (isatin C3), 154.6 (isatin C4), 149.3 (isatin C7a), 142.6 (phenyl
C1), 141.5 (isatin C6), 137.4 (phenyl C3), 129.5 (phenyl C2), 129.1 (phenyl C5), 128.8 (isatin C7), 127.7
(phenyl C6), 127.3 (phenyl C4), 116.5 (isatin C5), 110.3 (isatin C3a), 62.3 (OCH3), 35.9 (COOH-CH2CH2), 31.0 (COOH-CH2-CH2), 15.6 (CH3) ppm. EI-MS m/z 339 (M+, 100%), 311 (75), 293 (10), 277 (77).
HRMS (ESI) calcd for C19H18NO5 (MH+), 340.1185; found, 340.1187. HPLC purity: 99.4%, Rt=5.579 (1%
solvent B in solvent A).
3-(3-(2,3-Dioxoindolin-5-yl)phenyl)propanoic acid (37)
Following the general procedure 3 using 5-bromoindoline-2,3-dione 33 (100 mg, 0.442 mmol), 3-(3boronophenyl)propanoic acid 27 (102.9 mg, 0.530 mmol), tetrakis(triphenylphosphine)palladium(0) (25.5
mg, 0.022 mmol) and potassium phosphate (281.5 mg, 1.326 mmol) and heating for 4 h, the acid 37 was
isolated as an orange solid (84.8 mg, 65%), mp: 182-183 ºC; IR (cm-1): υ 3185 (m, NH), 2989 (m, OH),
1714 (s, C=O), 1684 (s, C=O). 1H NMR (DMSO-d6), δ: 11.14 (s, NH), 7.89 (dd, J = 8.2, 1.8 Hz, 1H,
isatin_6 H), 7.77 (d, J = 1.4 Hz, 1H, isatin_4 H), 7.53 (s, 1H, phenyl_2 H), 7.46 (d, J = 7.6 Hz, 1H,

phenyl_4 H), 7.35 (t, J = 7.5 Hz, 1H, phenyl_5 H), 7.21 (d, J = 7.5 Hz, 1H, phenyl_6 H), 6.99 (d, J = 7.9
Hz, 1H, isatin_7 H), 2.88 (t, J = 7.6 Hz, 2H, COOH-CH2-CH2), 2.59 (t, J = 7.5 Hz, 2H, COOH-CH2-CH2).
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C NMR, δ: 184.9 (COOH), 174.4 (isatin C3), 160.0 (isatin C2), 150.4 (isatin C7a), 142.2 (phenyl C3),

139.1 (phenyl C1), 136.9 (isatin C6), 135.4 (isatin C5), 129.4 (phenyl C5), 127.9 (phenyl C6), 126.7
(phenyl C2), 124.4 (phenyl C4), 122.9 (isatin C4), 118.9 (isatin C3a), 113.1 (isatin C7), 35.7 (COOH-CH2CH2), 30.9 (COOH-CH2-CH2) ppm. EI-MS m/z 295 (M+, 40), 267 (100%), 250 (95), 207 (20), 193 (25).
HRMS (ESI) calcd for C17H14NO4 (MH+), 296.0914; found, 296.0912. HPLC purity: 98.2%, Rt=7.237 (1%
solvent B in solvent A).
3-(3-(3-Methyl-8-oxo-7-pivaloyl-7-azabicyclo[4.2.0] octa-1,3,5-trien-5yl)phenyl)propanoic acid (38)
Under a N2 atmosphere, a 25 mL round bottom flask was charged with the β-lactam derivative 12 (100 mg,
0.339

mmol),

3-(3-boronophenyl)propanoic

acid

27

(72.3

mg,

0.372

mmol),

tetrakis(triphenylphosphine)palladium(0) (19.6 mg, 0.016 mmol) and potassium phosphate (215.9 mg, 1.02
mmol). A mixture of 1,4-dioxane (10 mL) and water (3 mL) was added and the reaction mixture was
degassed by flushing N2 through a needle for 10 min. The flask was then sealed with a rubber cap, heated at
85 ºC for 18 h. The solvent was then concentrated under reduced pressure and the flask was cooled to 0 ºC.
Chilled 1 N HCl (10 mL) was added dropwise with stirring, and the resulting solid was extracted with ethyl
acetate (2 x 15 mL). The combined organic layers were washed with water (15 mL), brine (15 mL) and
dried (MgSO4) and concentrated under reduced pressure. The resulting residue was subjected to a flash
column chromatography (50% CH2Cl2, 50% ethyl acetate and 1% acetic acid) to afford 38 as a pale yellow
oil (74.2 mg, 60%), IR (cm-1): υ 2959 (m, OH), 1696 (s, C=O), 1662 (s, C=O), 1481 (m, C-N). 1H NMR
(CDCl3), δ: 8.56 (s, 1H, COOH), 7.77 (s, 1H, H4), 7.32-7.29 (m, 2H, phenyl_5 H, H2), 7.20 (d, 1H, J = 7.5
Hz, phenyl_6 H), 7.19 (s, 1H, phenyl_2 H), 7.15 (d, 1H, J = 7.7 Hz, phenyl_4 H), 2.97 (t, 2H, J = 7.5 Hz,
COOH-CH2-CH2), 2.68 (t, 2H, J = 7.6 Hz, COOH-CH2-CH2), 2.37 (s, 3H, CH3), 1.03 (s, 9H, pivaloyl
3xCH3). 13C NMR, δ: 178.4 (pivaloyl C=O), 176.9 (COOH), 171.9 (azabicyclo C=O), 140.4 (phenyl C1),
140.1 (azabicyclo C6), 139.8 (phenyl C3), 136.4 (phenyl C5), 135.8 (azabicyclo C4), 133.1 (azabicyclo
C2), 130.9 (azabicyclo C3), 128.8 (azabicyclo C1), 128.7 (phenyl C2), 127.3 (phenyl C6), 126.8
(azabicyclo C5), 124.8 (phenyl C4), 39.3 (C(CH3)3), 35.8 (COOH-CH2-CH2), 30.9 (COOH-CH2-CH2), 27.2
(pivaloyl 3xCH3), 21.0 (CH3) ppm. EI-MS m/z 365 (M+, 60), 350 (70), 320 (50), 299 (25), 277 (100%), 235
(26), 220 (23), 193 (52). HRMS (ESI) calcd for C22H24NO4 (MH+), 366.1705; found, 366.1717. HPLC
purity: 98.9%, Rt=27.924 (3% solvent B in solvent A).
2-(3-Iodophenoxy)acetonitrile (42)
A solution of 3-iodophenol 41 (2.0 g, 9.09 mmol) and NaOH (0.91 g, 22.73 mmol) in dry DMF (25 mL)
was stirred vigorously for 30 min until the solution became pale brown. 2-Chloroacetonitrile (1.03 g, 0.86
mL, 13.64 mmol) was then added dropwise through a syringe and the mixture was further stirred for 18 h at

room temperature. The resulting brown solution was then poured onto crushed ice (100 mL), stirred for 30
min, and the resulting oil was extracted with ethyl acetate (2 x 25 mL). The combined organic layers were
washed with water (2 x 25 mL), brine (2 x 25 mL) and dried (MgSO4). The organic fraction was then
triturated with charcoal (0.5 g) and filtered through celite, and evaporated under reduced pressure to afford
2-(3-iodophenoxy)acetonitrile 42 as a yellow oil (1.88 g, 80%), IR (cm-1): υ 2942 (m, C-H aliphatic), 2246
(s, CN), 1203 (w, C-O). 1H NMR (CDCl3), δ: 7.37 (d, 1H, J = 7.7 Hz, phenoxy_6 H), 7.29 (s, 1H,
phenoxy_2 H), 7.02 (t, 1H, J = 7.9 Hz, phenoxy_5 H), 6.90 (d, 1H, J = 8.0 Hz, phenoxy_4 H), 4.68 (s, 2H,
CH2).
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C NMR, δ: 157.1 (phenoxy C1), 132.5 (phenoxy C5), 131.6 (phenoxy C4), 124.7 (phenoxy C2),

115.3 (CN), 114.6 (phenoxy C6), 94.9 (phenoxy C3), 54.0 (CH2) ppm. EI-MS m/z 259 (M+, 100%), 219
(27), 203 (5). HRMS (ESI) calcd for C8H7INO (MH+), 259.9572; found, 259.9565.
2-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetonitrile (40)
Under a N2 atmosphere, an oven dried 100 mL flask was charged with 2-(3-iodophenoxy)acetonitrile 42
(1.16 g, 4.48 mmol), bis(pinacolato)diboron 43 (4.55 g, 17.92 mmol), potassium acetate (1.76 g, 17.92
mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCl2(dppf)) (32.8 mg, 1 mol%).
Dry THF (50 mL) was added to the mixture, and the flask was heated at reflux for 18 h under N2
atmosphere. The solvent was then evaporated under reduced pressure, ethyl acetate (30 mL) was added and
the mixture was sonicated for 10 min and filtered. The filtrate was triturated with MgSO4 and charcoal (0.5
g), and filtered through a short pad of celite. The filtrate was then concentrated under reduced pressure and
the resulting residue was recrystallised from a mixture of ethyl acetate/hexane (3:2) to give the boronic
ester 40 as a pink solid (1.1 g, 95%), mp: 40-41 ºC; IR (cm-1): υ 2980 (m, C-H aliphatic), 2152 (m, CN),
1128 (w, C-O). 1H NMR (CDCl3), δ: 7.43 (d, 1H, J = 7.6 Hz, phenoxy_6 H), 7.39 (s, 1H, phenoxy_2 H),
7.08 (t, 1H, J = 7.9 Hz, phenoxy_5 H), 6.96 (d, 1H, J = 8.0 Hz, phenoxy_4 H), 4.76 (s, 2H, CH2), 1.26 (s,
12H, 4xCH3). 13C NMR, δ: 157.1 (phenoxy C1), 132.6 (phenoxy C3), 131.4 (phenoxy C5), 124.7 (phenoxy
C4), 114.8 (CN), 114.6 (phenoxy C2), 94.6 (phenoxy C6), 83.7 (dioxaborolan C4, C5), 53.9 (CH2), 25.2
(4xCH3) ppm. ESI-MS m/z 259 (M+). HRMS (ESI) calcd for C14H19BNO3 (MH+), 260.1458; found,
260.1462.
General procedure 4: Suzuki coupling of 6-bromobenzolactone derivatives 7 and 8 with
(3-(cyanomethoxy)phenyl)boronic acid 39 or ester 40
A round bottom 25 mL flask was charged with the appropriate dihydroisobenzofuran derivative (1 equiv),
(3-(cyanomethoxy)phenyl)boronic acid 39 (1 equiv) or 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)phenoxy)acetonitrile 40 (1.2 equiv), tetrakis(triphenylphosphine)palladium(0) (5 mol%), 1,4-dioxane (10
mL) was added and the flask was sealed with a rubber cap. The reaction mixture was degassed by flushing
N2 through a needle for 10 min. The flask was heated in an oil bath at 85 ºC. When all the solid was
dissolved, potassium phosphate (3 mmol, 636.8 mg) dissolved in water (5 mL) was added to the reaction
via a needle. The flask was then heated at 85 ºC for 7-15 h. The solvent was concentrated under reduced

pressure, and was added 1 M HCl (10 mL), the reaction mixture turned to a white turbid solution which
was then extracted with ethyl acetate (2 x 30 mL), washed with brine (2 x 10 mL) and dried (MgSO4). The
solvent was evaporated and the residue was subjected to flash column chromatography (40% ethyl acetate
in petroleum spirit).
2-(3-(4-Methoxy-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenoxy)acetonitrile (44)
Following the general procedure 4 using 6-bromo-7-methoxyisobenzofuran-1(3H)-one 7 (100 mg, 0.411
mmol),

(3-(cyanomethoxy)phenyl)boronic

acid

39

(72

mg,

0.411

mmol),

tetrakis(triphenylphosphine)palladium(0) (23.7 mg, 0.021 mmol) and heating for 15 h, the acetonitrile
intermediate 44 was isolated as a white solid (60.7 mg, 50%), mp: 103-104 ºC; IR (cm-1): υ 2920 (w, C-H
aliphatic), 2165 (m, CN), 1759 (s, C=O), 1212 (w, C-O). 1H NMR (CDCl3), δ: 7.74 (d, 1H, J = 7.7 Hz,
isobenzofuran_6 H), 7.43 (t, 1H, J = 8.0 Hz, phenyl_5 H), 7.25-7.23 (m, 2H, phenyl_4 H, isobenzofuran_7
H), 7.19 (s, 1H, phenyl_2 H), 7.02 (d, 1H, J = 8.2 Hz, phenyl_6 H), 5.30 (s, 2H, isobenzofuran CH2), 4.83
(s, 2H, CN-CH2), 3.90 (s, 3H, OCH3). 13C NMR, δ: 168.5 (C=O), 156.7 (phenyl C1), 156.4 (isobenzofuran
C4), 148.7 (isobenzofuran C7a), 138.7 (isobenzofuran C6), 137.4 (phenyl C5), 134.7 (isobenzofuran C5),
129.8 (phenyl C4), 124.1 (phenyl C3), 117.9 (phenyl C6), 117.1 (phenyl C2), 116.1 (CN), 115.1
(isobenzofuran C3a), 114.5 (isobenzofuran C7), 68.7 (isobenzofuran C1), 62.7 (CN-CH2), 53.7 (OCH3)
ppm. EI-MS m/z 295 (M+, 15), 255 (100%), 237 (13), 208 (10), 180 (16). HRMS (ESI) calcd for
C17H14NO4 (MH+), 296.0914; found, 296.0913. HPLC purity: 98.3%, Rt=16.676 (1% solvent B in solvent
A).
2-(3-(4-Methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenoxy)acetonitrile (45)
Following the general procedure 4 using 6-bromo-7-methoxyisobenzofuran-1(3H)-one 8 (100 mg, 0.358
mmol), 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy) acetonitrile 40 (111.4 mg, 0.430
mmol), tetrakis(triphenylphosphine)palladium(0) (20.7 mg, 0.018 mmol) and heating for 7 h, the
acetonitrile intermediate 45 was isolated as white solid (93.4 mg, 76%), mp: 99-100 ºC; IR (cm-1): υ 2972
(w, C-H aliphatic), 2169 (m, CN), 1743 (s, C=O). 1H NMR (CDCl3), δ: 7.51 (d, 1H, J = 7.7 Hz,
isobenzofuran_6 H), 7.43 (t, 1H, J = 7.9 Hz, phenyl_5 H), 7.33 (d, 1H, J = 7.7 Hz, isobenzofuran_7 H),
7.02 (d, 2H, J = 8.0 Hz, phenyl_4,6 H), 6.93 (s, 1H, phenyl_2 H), 5.28 (s, 2H, isobenzofuran CH2), 4.83 (s,
2H, CN-CH2), 2.60 (s, 3H, CH3). 13C NMR, δ: 171.4 (C=O), 156.7 (phenyl C1), 146.7 (isobenzofuran C7a),
142.8 (isobenzofuran C4), 142.1 (isobenzofuran C5), 137.6 (phenyl C3), 135.6 (phenyl C5), 130.1
(isobenzofuran C3a), 124.4 (phenyl C4), 124.1 (isobenzofuran C6), 119.4 (isobenzofuran C7), 116.4
(phenyl C2), 115.3 (CN), 114.1 (phenyl C6), 68.6 (isobenzofuran C1), 53.9 (CN-CH2), 15.0 (CH3) ppm. EIMS m/z 279 (M+, 90), 239 (100%), 223 (15), 195 (12), 165 (24). HRMS (ESI) calcd for C17H14NO3 (MH+),
280.0974; found, 280.0966. HPLC purity: 98.1%, Rt=11.021 (1% solvent B in solvent A).

General procedure 5: synthesis of the benzolactone-tetrazole conjugates 46 and 47 using
sodium azide method
Under a N2 atmosphere, a round bottom flask (25 mL) was charged with the appropriate acetonitrile
derivative 44-45 (0.186 mmol), sodium azide (48.4 mg, 0.744 mmol), amonium chloride (39.4 mg, 0.744
mmol), DMF (10 mL) and a catalytic amount of glacial acetic acid (5-10 drops), and the reaction mixture
was then heated at reflux for 24 h. DMF was concentrated under reduced pressure and the residue was dried
by vacuum. Ethanol was added to the resulting dry residue and the mixture was sonicated for 10 min,
filtered and the ethanol solution was concentrated and subjected to PLC (90% CH2Cl2, 10% ethanol and
0.1% TFA) to yield the tetrazole conjugate.
6-(3-((1H-Tetrazol-5-yl)methoxy)phenyl)-7-methoxyisobenzofuran-1(3H)-one (46)
Following

the

general

procedure

5

using

2-(3-(4-methoxy-3-oxo-1,3-dihydroisobenzofuran-5-

yl)phenoxy)acetonitrile 44 (55 mg), the tetrazole conjugate 46 was isolated as a pale yellow solid (21.4 mg,
34%), mp: 130-131 ºC; IR (cm-1): υ 3404 (w, NH), 2907 (w, C-H aliphatic), 1751 (s, C=O), 1660 (m,
C=N), 1134 (w, C-O). 1H NMR (CD3OD), δ: 7.72 (d, 1H, J = 7.7 Hz, isobenzofuran_5 H), 7.42 (t, 1H, J =
7.9 Hz, phenyl_5 H), 7.37 (d, 1H, J = 7.7 Hz, isobenzofuran_4 H), 7.22-7.17 (m, 2H, phenyl_2,4 H), 7.10
(d, 1H, J = 8.2 Hz, phenyl_6 H), 5.50 (s, 2H, isobenzofuran CH2), 5.34 (s, 2H, OCH2), 3.78 (s, 3H, OCH3).
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C NMR, δ: 169.7 (C=O), 157.9 (phenyl C3), 156.5 (isobenzofuran C7), 149.6 (tetrazole C), 138.7

(isobenzofuran C3a), 137.7 (isobenzofuran C5), 135.1 (phenyl C5), 129.5 (isobenzofuran C6), 129.4
(phenyl C6), 123.0 (phenyl C1), 117.6 (phenyl C4), 117.5 (phenyl C2), 115.9 (isobenzofuran C7a), 113.9
(isobenzofuran C4), 69.3 (isobenzofuran C3), 61.7 (tetrazole-CH2-O), 59.9 (OCH3) ppm. EI-MS m/z 338
(M+, 14), 255 (100%), 239 (10), 211 (12), 195 (11). HRMS (ESI) calcd for C17H15N4O4 (MH+), 339.1093;
found, 339.1107. HPLC purity: 96.3%, Rt=16.339 (5% solvent B in solvent A).
6-(3-((1H-Tetrazol-5-yl)methoxy)phenyl)-7-methylisobenzofuran-1(3H)-one (47)
Following

the

general

procedure

5

using

2-(3-(4-methyl-3-oxo-1,3-dihydroisobenzofuran-5-

yl)phenoxy)acetonitrile 45 (51.9 mg), the final tetrazole conjugate 47 was isolated as a pale yellow gummy
solid (21 mg, 35%), IR (cm-1): υ 3392 (m, NH), 2988 (w, C-H aliphatic), 1741 (s, C=O), 1668 (m, C=N),
1212 (w, C-O). 1H NMR (CD3OD), δ: 7.58 (d, 1H, J = 7.7 Hz, isobenzofuran_5 H), 7.48 (d, 1H, J = 7.7 Hz,
isobenzofuran_4 H), 7.44 (t, 1H, J = 7.9 Hz, phenyl_5 H), 7.12 (d, 1H, J = 7.9 Hz, phenyl_6 H), 7.03 (s,
1H, phenyl_2 H), 6.99 (d, 1H, J = 7.5 Hz, phenyl_4 H), 5.51 (s, 2H, isobenzofuran CH2), 5.36 (s, 2H, OCH2), 2.55 (s, 3H, CH3).
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C NMR (DMSO-d6), δ: 170.9 (C=O), 162.4 (phenyl C3), 157.3 (tetrazole C),

147.2 (isobenzofuran C3a), 142.1 (isobenzofuran C7), 141.1 (isobenzofuran C6), 135.7 (phenyl C5), 135.4
(isobenzofuran C5), 129.7 (phenyl C1), 122.9 (isobenzofuran C7a), 122.7 (phenyl C6), 120.8
(isobenzofuran C4), 115.8 (phenyl C2), 114.1 (phenyl C4), 68.5 (isobenzofuran C3), 59.3 (tetrazole-CH2O), 14.4 (CH3) ppm. EI-MS m/z 322 (M+, 50), 239 (75), 223 (26), 195 (60), 165 (100%). HRMS (ESI)

calcd for C17H15N4O3 (MH+), 323.1144; found, 323.1138. HPLC purity: 98.7%, Rt=10.695 (5% solvent B
in solvent A).
5-((3-Iodophenoxy)methyl)-1H-tetrazole (48)
In a round bottom 50 mL flask, a solution of 2-(3-iodophenoxy)acetonitrile 42 (1.6 g, 6.18 mmol), sodium
azide (1.6 g, 24.7 mmol) and amonium chloride (1.3 g, 24.7 mmol) in dry DMF (25 mL), containing few
drops of glacial acetic acid, was heated at reflux for 14 h under a N2 atmosphere. The solvent was then
concentrated under reduced pressure, and the resulting residue was dried under vacuum. Ethanol (25 mL)
was added to the residue and the mixture was sonicated for 10 min, filtered and ethanol was evaporated
under reduced pressure resulting in a white fluffy solid of the tetrazole intermediate 48 (1.5 g, 80%), mp:
99-100 ºC; IR (cm-1): υ 2995 (w, NH), 1589 (m, C=N), 1240 (w, C-O). 1H NMR (CD3OD), δ: 7.46 (s, 1H,
phenoxy_2 H), 7.39 (t, 1H, J = 7.0 Hz, phenoxy_5 H), 7.09-7.08 (m, 2H, phenoxy_4,6 H), 5.47 (s, 2H,
CH2).
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C NMR, δ: 159.7 (phenoxy C1), 155.3 (tetrazole C), 132.4 (phenoxy C4), 132.2 (phenoxy C5),

125.4 (phenoxy C2), 115.3 (phenoxy C6), 94.9 (phenoxy C3), 61.1 (CH2) ppm. EI-MS m/z 302 (M+,
100%), 220 (80), 203 (10). HRMS (ESI) calcd for C8H8IN4O (MH+), 302.9743; found, 302.9734.
Potassium 5-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)tetrazol-1ide (49)
Under a N2 atmosphere, an oven dried 100 mL flask was charged with 5-((3-iodophenoxy)methyl)-1Htetrazole 48 (960 mg, 3.179 mmol), bis(pinacolato)diboron 43 (3.2 g, 12.72 mmol), potassium acetate (1.25
g, 12.72 mmol) and PdCl2(dppf) (23.3 mg, 1 mol%). Dry THF (30 mL) was added to the mixture, and the
flask was heated at reflux for 18 h under a N2 atmosphere. The solvent was then concentrated under
reduced pressure. Ethanol (30 mL) was added to the resulting residue and the mixture was further heated at
reflux for 10 min, filtered hot and concentrated under reduced pressure to afford a white solid of the
boronic ester potassium salt 49 (1.1 g, 99%), mp: >250 ºC ; IR (cm-1): υ 2983 (s, C-H aliphatic), 1680 (m,
C=N), 1233 (w, C-O). 1H NMR (CD3OD), δ: 7.38 (s, 1H, phenoxy_2 H), 7.28 (d, 1H, J = 7.1 Hz,
phenoxy_6 H), 7.04-6.99 (m, 2H, phenoxy_4,5 H), 5.25 (s, 2H, CH2), 1.90 (s, 12H, 4xCH3). 13C NMR, δ:
178.5 (phenoxy C1), 159.5 (tetrazole C), 158.3 (phenoxy C3), 130.8 (phenoxy C5), 130.2 (phenoxy C4),
124.2 (phenoxy C6), 114.2 (phenoxy C2), 93.6 (dioxaborolan C4, C5), 61.2 (CH2), 22.6 (4xCH3) ppm. ESIMS m/z 301.1 (M+K+).
General procedure 6: synthesis of the benzolactone-tetrazole conjugates 50 and 51 using
the coupling method:
Under a N2 atmosphere, a mixture of the appropriate bromoisobenzofuran-1(3H)-one derivative (1 mmol)
and potassium 5-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)tetrazol-1-ide 49 (374
mg, 1.1 mmol), tetrakis(triphenylphosphine)palladium(0) (80.9 mg, 7 mol%) and potassium phosphate
(636.8 mg, 3 mmol) was added to a solvent mixture of 1,4-dioxane (25 mL) and water (10 mL) in a 50 mL

round bottom flask. The reaction mixture was degassed by flushing N2 through a needle for 10 min, the
flask was then sealed with a rubber cap, heated at 85 ºC for 20-24 h. The solvent was then concentrated
under reduced pressure. Saturated NaHCO3 (25 mL) was added to the resulting residues, and the mixture
sonicated for 15 min, before the turbid solution was washed with CH2Cl2 (25 mL). The aqueous layer was
filtered, cooled to 0 ºC using an ice bath, and the filtrate was then neutralized with 2 M HCl. The resulting
white solid was collected by vacuum filtration, washed with chilled methanol and dried under vacuum to
afford the tetrazoles.
6-(3-((1H-Tetrazol-5-yl)methoxy)phenyl)-5,7-dimethoxyisobenzofuran-1(3H)-one (50)
Following the general procedure 6 using 6-bromo-5,7-dimethoxyisobenzofuran-1(3H)-one 10 (1 mmol, 273
mg) and heating for 24 h, the final tetrazole conjugate 50 was isolated as a white solid (195 mg, 53%), mp:
charring; IR (cm-1): υ 3204 (w, NH), 1740 (s, C=O), 1614 (m, C=N), 1218 (w, C-O). 1H NMR (DMSO-d6),
δ: 7.36 (t, 1H, J = 7.9 Hz, phenyl_5 H), 7.05 (d, 1H, J = 8.0 Hz, phenyl_6 H), 7.00 (s, 1H, phenyl_2 H),
6.93 (d, 1H, J = 7.7 Hz, phenyl_4 H), 6.82 (s, 1H, isobenzofuran_4 H), 5.49 (s, 2H, isobenzofuran CH2),
5.12 (s, 2H, OCH2), 3.90 (s, 3H, isobenzofuran_7 OCH3), 3.89 (s, 3H, isobenzofuran_5 OCH3). 13C NMR,
δ: 167.9 (C=O), 162.6 (isobenzofuran C5), 158.9 (phenyl C3), 157.4 (isobenzofuran C7), 153.6 (tetrazole
C), 149.2 (isobenzofuran C3a), 134.9 (phenyl C5), 129.5 (phenyl C6), 122.8 (phenyl C4), 115.9 (phenyl
C10), 115.7 (phenyl C11), 114.1 (isobenzofuran C7a), 104.7 (isobenzofuran C4), 96.2 (isobenzofuran C6),
67.8 (isobenzofuran C3), 59.2 (tetrazole-CH2-O), 56.6 (isobenzofuran_7 OCH3), 56.1 (isobenzofuran_5
OCH3) ppm. ESI-MS m/z 367.1 (M-H+). HRMS (ESI) calcd for C18H15N4O5 (M-H+), 367.1042; found,
367.1038. HPLC purity: 95.2%, Rt=18.896 (10% solvent B in solvent A).
6-(3-((1H-Tetrazol-5-yl)methoxy)phenyl)isobenzofuran-1(3H)-one (51)
Following the general procedure 6 using 6-bromoisobenzofuran-1(3H)-one 28 (213 mg, 1 mmol) and
heating for 20 h, the final tetrazole conjugate 51 was isolated as a white solid (181 mg, 59%), mp: charring;
IR (cm-1): υ 3195 (w, NH), 1751 (s, C=O), 1653 (m, C=N). 1H NMR (CD3OD), δ: 8.07 (s, 1H,
isobenzofuran_7 H), 7.99 (d, 1H, J = 8.0 Hz, isobenzofuran_5 H), 7.67 (d, 1H, J = 8.0 Hz, isobenzofuran_4
H), 7.38 (t, 1H, J = 7.9 Hz, phenyl_5 H), 7.33 (s, 1H, phenyl_2 H), 7.24 (d, 1H, J = 7.5 Hz, phenyl_6 H),
7.09 (d, 1H, J = 8.0 Hz, phenyl_4 H), 5.42 (s, 2H, isobenzofuran CH2), 5.37 (s, 2H, O-CH2). 13C NMR, δ:
171.9 (C=O), 159.3 (phenyl C3), 146.3 (tetrazole C), 142.4 (isobenzofuran C3a), 140.9 (isobenzofuran C6),
133.2 (phenyl C1), 129.7 isobenzofuran C5), 125.9 (phenyl C5), 122.9 (phenyl C6), 122.7 (isobenzofuran
C7), 122.6 (isobenzofuran C7a), 119.7 (phenyl C2), 114.4 (isobenzofuran C4), 113.7 (phenyl C4), 69.9
(isobenzofuran C3), 61.1 (tetrazole-CH2-O) ppm. ESI-MS m/z 307.1 (M-H+). HRMS (ESI) calcd for
C16H11N4O3 (M-H+), 307.0831; found, 307.0826. HPLC purity: 98.8%, Rt=13.175 (5% solvent B in solvent
A).

General procedure 7: Suzuki coupling of the 5-bromoisatin derivatives 17, 20, 26 and 33
with (3-(cyanomethoxy)phenyl)boronic acid 39:
Under a N2 atmosphere, a 25 mL flask was charged with the 5-bromoisatin derivative (1 equiv), (3(cyanomethoxy)phenyl)boronic acid 39 (1 equiv), tetrakis(triphenylphosphine)palladium(0) (5 mol%),
potassium phosphate (3 equiv) and a mixture of diglyme (3 mL) and water (3 mL), and the reaction mixture
was degassed by flushing N2 through a needle for 10 min. The flask was then sealed and heated at 85 ºC for
5-9 h. After cooling to room temperature, the solvent was concentrated under reduced pressure, and 1 N
HCl (15 mL) was added. The suspended solid was either collected by filtration or extracted with ethyl
acetate (2 x 25 mL). The combined organic layers were dried (MgSO4) and evaporated under reduced
pressure. The combined residues were adsorbed onto silica and subjected to flash column chromatography
(40% ethyl acetate in petroleum spirit) to yield the acetonitrile derivatives.

2-(3-(4,6-Dimethoxy-2,3-dioxoindolin-5-yl)phenoxy)acetonitrile (52)
Following the general procedure 7 using 5-bromo-4,6-dimethoxyindoline-2,3-dione 17 (40 mg, 0.139
mmol),

(3-(cyanomethoxy)phenyl)boronic

acid

39

(24.6

mg,

0.139

mmol),

tetrakis(triphenylphosphine)palladium(0) (8 mg, 0.007 mmol), potassium phosphate (88.5 mg, 0.417 mmol)
and heating for 9 h, the acetonitrile intermediate 52 could not be isolated. Analysis of the crude mixture:
EI-MS m/z 338 (M+, 17), 309 (7), 382 (66), 257 (100%), 225 (25). HRMS (ESI) calcd for C18H15N2O5
(MH+), 339.0981; found, 339.0980. This sample was collected from the reaction mixture before
purification, but could not be further purified and was not sufficiently stable to perform NMR experiments.
2-(3-(7-Methyl-2,3-dioxoindolin-5-yl)phenoxy)acetonitrile (53)
Following the general procedure 7 using 5-bromo-7-methylindoline-2,3-dione 20 (100 mg, 0.416 mmol),
(3-(cyanomethoxy)phenyl)boronic

acid

39

(73.6

mg,

0.416

mmol),

tetrakis(triphenylphosphine)palladium(0) (24 mg, 0.021 mmol), potassium phosphate (264.9 mg, 1.248
mmol) and heating for 5 h, the acetonitrile intermediate 53 was isolated as a red solid (63.2 mg, 52%), mp:
208-209 ºC; IR (cm-1): υ 3185 (w, NH), 2365 (m, CN), 1750 (s, C=O), 1587 (s, C=O). 1H NMR (acetoned6), δ: 10.13 (s, NH), 7.83 (s, 1H, isatin_4 H), 7.68 (s, 1H, isatin_C6), 7.47 (t, J = 7.8 Hz, 1H, phenoxy_5
H), 7.40-7.38 (m, 2H, phenoxy_2,4 H), 7.09 (d, J = 8.0 Hz, 1H, phenoxy_6 H), 5.21 (s, 2H, CH2), 2.39 (s,
3H, CH3). 13C NMR, δ: 185.1 (isatin C3), 160.5 (phenoxy C1), 158.6 (isatin C2), 149.8 (isatin C7a), 142.4
(phenoxy C3), 138.9 (isatin C7), 136.4 (isatin C6), 131.3 (isatin C5), 123.3 (phenoxy C5), 121.8 (isatin
C4), 121.2 (phenoxy C4), 119.5 (phenoxy C2), 116.7 (phenoxy C6), 115.3 (CN), 114.1 (isatin C3a), 54.7
(CH2), 15.8 (CH3) ppm. EI-MS m/z 292 (M+, 93), 264 (80), 236 (100%), 196 (17), 180 (11). HRMS (ESI)
calcd for C17H13N2O3 (MH+), 293.0926; found, 293.0931. HPLC purity: 97.9%, Rt=13.070 (2.5% solvent C
in solvent A).

2-(3-(4-Methoxy-7-methyl-2,3-dioxoindolin-5-yl)phenoxy)acetonitrile (54)
Following the general procedure 7 using 5-bromo-4-methoxy-7-methylindoline-2,3-dione 26 (100 mg,
0.370

mmol),

(3-(cyanomethoxy)phenyl)boronic

acid

39

(65.5

mg,

0.370

mmol),

tetrakis(triphenylphosphine)palladium(0) (21.4 mg, 0.019 mmol), potassium phosphate (235.6 mg, 1.11
mmol) and heating for 8 h, the acetonitrile intermediate 54 was isolated as a red solid (41.7 mg, 35%), mp:
179-180 ºC; IR (cm-1): υ 3190 (m, NH), 2166 (w, CN), 1706 (s, C=O), 1611 (s, C=O), 1294 (w, C-O). 1H
NMR (CD3OD), δ: 7.40 (s, 1H, isatin_6 H), 7.38 (t, J = 8.2 Hz, 1H, phenoxy_5 H), 7.12 (d, J = 8.2 Hz, 1H,
phenoxy_4 H), 7.11 (s, 1H, phenoxy_2 H), 7.01 (d, J = 8.3 Hz, 1H, phenoxy_6 H), 5.00 (s, 2H, CH2), 3.91
(s, 3H, OCH3), 2.22 (s, 3H, CH3). 13C NMR, δ: 160.2 (isatin C3), 156.7 (phenoxy C1), 154.9 (isatin C2),
148.6 (isatin C4), 142.1 (isatin C7a), 138.9 (isatin C6), 137.8 (phenoxy C3), 129.2 (phenoxy C5), 123.4
(isatin C5), 120.5 (isatin C7), 115.9 (phenoxy C4), 115.7 (phenoxy C6), 115.5 (phenoxy C2), 113.7 (CN),
109.5 (isatin C3a), 61.1 (CH2), 53.3 (OCH3), 13.7 (CH3) ppm. EI-MS m/z 322 (M+, 74), 294 (68), 280 (4),
254 (7), 226 (100%), 211 (11). HRMS (ESI) calcd for C18H15N2O4 (MH+), 323.1032; found, 323.1018.
HPLC purity: 99.5%, Rt=11.766 (2.5% isopropanol in solvent A).
2-(3-(2,3-Dioxoindolin-5-yl)phenoxy)acetonitrile (55)
Following the general procedure 7 using 5-bromoindoline-2,3-dione 33 (100 mg, 0.442 mmol), (3(cyanomethoxy)phenyl)boronic acid 39 (78.2 mg, 0.442 mmol), tetrakis(triphenylphosphine)palladium(0)
(25.5 mg, 0.022 mmol), potassium phosphate (281.5 mg, 1.326 mmol) and heating for 5 h, the acetonitrile
intermediate 55 was isolated as a red solid (73.7 mg, 60%), mp: 205-206 ºC; IR (cm-1): υ 3168 (w, NH),
2166 (m, CN), 1732 (s, C=O), 1621 (s, C=O). 1H NMR (acetone-d6), δ: 10.04 (s, NH), 7.95 (d, J = 8.2, 1H,
phenoxy_4 H), 7.83 (s, 1H, phenoxy_2 H), 7.47 (t, J = 8.2 Hz, 1H, phenoxy_5 H), 7.39-7.38 (m, 2H,
isatin_4,7H), 7.14 (d, J = 8.2 Hz, phenoxy_6H), 7.09 (d, J = 8.6 Hz, 1H, isatin_6H), 5.21 (s, 2H, CH2). 13C
NMR, δ: 184.1 (isatin C3), 159.6 (phenoxy C1), 157.8 (isatin C2), 150.4 (isatin C7a), 141.5 (phenoxy C3),
137.0 (phenoxy C4), 135.7 (phenoxy C2), 130.6 (phenoxy C5), 123.1 (isatin C5), 121.0 (isatin C7), 118.9
(phenoxy C6), 116.0 (CN), 114.6 (isatin C3a), 113.1 (isatin C4), 112.9 (isatin C6), 53.8 (CH2) ppm. EI-MS
m/z 278 (M+, 46), 250 (100%), 207 (5), 182 (49). HRMS (ESI) calcd for C16H11N2O3 (MH+), 279.0770;
found, 279.0759. HPLC purity: 99.7%, Rt=20.046 (2.5% solvent C in solvent A).
3'-(Cyanomethoxy)-5-methyl-2-pivalamido-[1,1'-biphenyl] -3-carboxylic acid (59)
Under a N2 atmosphere, a 25 mL round bottom flask was charged with the β-lactam derivative 12 (100 mg,
0.339 mmol), the boronic ester 40 (96.6 mg, 0.373 mmol), tetrakis(triphenylphosphine)palladium(0) (19.6
mg, 0.016 mmol) and potassium phosphate (215.9 mg, 1.02 mmol). A mixture of 1,4-dioxane (10 mL) and
water (3 mL) was added and the reaction mixture was degassed by flushing N2 through a needle for 10 min.
The flask was then sealed with a rubber cap, heated at 85 ºC for 12 h. The solvent was then concentrated
under reduced pressure and 1 N HCl (10 mL) was added dropwise to the resulting residue which was
extracted with ethyl acetate (2 x 15 mL). The combined organic layers were washed with water (15 mL),

brine (15 mL) and dried (MgSO4). The mixture was then concentrated under reduced pressure, and the
resulting residue was subjected to a flash column chromatography and elution with 90% CH2Cl2, 10%
ethanol and 0.1% TFA yielded 59 as a pale yellow oil (59.4 mg, 48%), IR (cm-1): υ 3328 (m, NH), 2967
(m, OH), 2200 (m, CN), 1646 (w, NH), 1411 (w, C-N). 1H NMR (CDCl3), δ: 8.61 (s, 1H, COOH), 7.53 (s,
1H, phenyl_6 H), 7.32 (t, 1H, J = 7.7 Hz, phenyl_5' H), 7.15 (s, 1H, phenyl_4 H), 7.01 (d, 1H, J = 7.5 Hz,
phenyl_6'H), 6.92-6.90 (m, 2H, phenyl_2', 4'), 6.47 (s, 1H, NH), 4.73 (s, 2H, CH2), 2.28 (s, 3H, CH3), 0.97
(s, 9H, pivaloyl 3xCH3). 13C NMR, δ: 177.7 (pivaloyl C=O), 176.7 (COOH), 173.8 (C3'), 156.4 (C2), 141.7
(C5), 137.8 (C1), 135.7 (C6'), 133.2 (C4), 130.5 (C6), 129.7 (C1'), 129.6 (C6'), 123.4 (C4'), 115.6 (CN),
115.1 (C3), 113.3 (C2'), 53.5 (CH2), 38.9 (C(CH3)3), 26.9 (pivalamido 3xCH3), 20.8 (CH3) ppm. ESI-MS
m/z 365.0 (M-H+). HRMS (ESI) calcd for C21H23N2O4 (MH+), 367.1658; found, 367.1656. HPLC purity:
99.4%, Rt=17.599 (2% solvent B in solvent A).
Antiviral assay
CHIKV Indian Ocean strain 899 (Genbank FJ959103.1) was generously provided by Prof. S. Günther
(Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany) (Panning M et al, Emerging
Infectious Diseases 2008). BGM cells were maintained in cell growth medium composed of minimum
essential medium (MEM Rega-3, Gibco, Belgium) supplemented with 10% Foetal Bovine Serum (FBS,
Integro, The Netherlands), 1% L-glutamine (Gibco), and 1% sodium bicarbonate (Gibco). The antiviral
assays were performed in virus growth medium which is the respective cell growth medium supplemented
with 2% (instead of 10%) FBS. Cell cultures were maintained at 37 °C in an atmosphere of 5% CO2 and
95-99% humidity.
BGM cells were seeded in 96-well tissue culture plates (Becton Dickinson, Aalst, Belgium) at a density of
2.5 × 104 cells/well in 100 µl assay medium and were allowed to adhere overnight. Next, a compound
dilution series was prepared in the medium on top of the cells after which the cultures were infected with
0.001 MOI of CHIKV 899 inoculum in 100 µl assay medium. On day 5 post-infection (p.i.), the plates were
processed using the MTS/PMS method as described by the manufacturer (Promega, The Netherlands). The
50% effective concentration (EC50), which is defined as the compound concentration that is required to
inhibit virus-induced cell death by 50%, was determined using logarithmic interpolation. Potential
cytotoxic/cytostatic effects of selected compounds were also evaluated in uninfected cells by means of the
MTS/PMS method. The 50% cytotoxic concentration (CC50; i.e., the concentration that reduces the overall
metabolic activity of the cells by 50%) was calculated using logarithmic interpolation. All assay wells were
checked microscopically for minor signs of virus-induced CPE or possible alterations to the cell or
monolayer morphology caused by the compound.
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